Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as NP101 Sumatriptan Iontophoretic Transdermal Patch
NP101 Sumatriptan Iontophoretic Patch · 2 trials · 1 indication
Subjects whose headache severity score equaled zero (0) two hours post patch activation and who had not received any rescue medication before their two-hour assessment.
| Arm | Type | Description |
|---|---|---|
| Sumatriptan | EXPERIMENTAL | NP101 - sumatriptan iontophoretic transdermal patch |
| Placebo | PLACEBO_COMPARATOR | Placebo iontophoretic transdermal patch |
| Period 1 | EXPERIMENTAL | NP101 Patch |
| Period 2 | EXPERIMENTAL | NP101 Patch |
| Period 3 | EXPERIMENTAL | NP101 Patch |
| Period 4 | EXPERIMENTAL | NP101 Patch |
| Period 5 | EXPERIMENTAL | NP101 Patch |
| Name | Type | Description |
|---|---|---|
| NP101 - Sumatriptan iontophoretic transdermal patch | DRUG | Sumatriptan iontophoretic transdermal patch |
| Placebo | DRUG | NP101 Placebo iontophoretic transdermal patch |
| NP101 Sumatriptan Iontophoretic Transdermal Patch | DRUG | NP101 transdermal patch delivering sumatriptan for 4 hours. |
Inclusion Criteria: * Subject is an adult male or female, age range 18 years to 65 years. * Subject has a diagnosis of migraine headache, with or without aura, as defined in the ICDH-II and the diagnosis was made before the age of 50. * Subject typically experiences moderate to severe headaches dur...
NP101 Sumatriptan Iontophoretic Patch is being developed for the treatment of acute migraine disorders. It is a transdermal patch formulation of sumatriptan designed to deliver the drug through the skin using iontophoresis. The patch is intended for adults with migraine.
NP101 Sumatriptan Iontophoretic Patch uses iontophoresis to deliver sumatriptan, a small molecule, through the skin. Iontophoresis applies a low electrical current to drive charged drug molecules across the skin barrier. Sumatriptan is a serotonin receptor agonist that treats acute migraine.
NP101 Sumatriptan Iontophoretic Patch is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. Teva is a global pharmaceutical company focused on generic and specialty medicines, including treatments for neurological conditions such as migraine.
NP101 Sumatriptan Iontophoretic Patch is in Phase 3 clinical development. It has not been approved by the FDA and remains an investigational therapy. The Phase 3 program includes a completed efficacy and tolerability trial in acute migraine.
NP101 Sumatriptan Iontophoretic Patch has been studied in two completed clinical trials: NCT00724815, a Phase 3 efficacy and tolerability trial in acute migraine with 530 participants, and NCT00720018, a Phase 1 pharmacokinetic study in 4 healthy volunteers. Both trials were conducted in the United States.
Yes, NP101 Sumatriptan Iontophoretic Patch is also known as NP101 Sumatriptan Iontophoretic Transdermal Patch, NP101 - Sumatriptan iontophoretic transdermal patch, and NP101- Sumatriptan iontophoretic patch. These names refer to the same investigational product developed by Teva for acute migraine.